Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 8, 2014, Pages 2191-2196

  Tatlı, Ali Murat ^a   Coşkun, Hasan Şenol ^b   Uysal, Mükremin ^c   Arslan, Deniz ^a   Göksu, Sema Sezgin ^a   Gündüz, Şeyda Güenay ^b   Çakal, Selda ^b   Bozcuk, Hakan Şat ^b   Savaş, Burhan ^b  

^a Department of Medical Oncology Van Training and Research Hospital ^*  (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

^c AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

FOLFIRI; Induction treatment; Maintenance treatment; Metastatic colorectal carcinoma

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG RESPONSE; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84907164397     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
4. Malvezzi M, Arfe A, Bertuccio P, Levi F, LaVecchia C, Negri E. European cancer mortality predictions for the year 2011. Ann Oncol 2011; 22: 947-956.
5. Berry SR, Cosby R, Asmis TR, Chan KK, Hammad N, Krzyzanowska MK. Randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC): A meta-analysis from the Cancer Care Ontario program in evidence-based care (abstract). J Clin Oncol 2013; 31: Suppl; abstr 3534.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
7. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
8. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
9. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ. For the FOCUS Trial Investigators and the National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.
10. Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Niclella D, Aglietta M, Lonardi S, Corsi D, Turci D, Beretta GD, Fornarini G, Dapretto E, Floriani I, Zaniboni A; Italian Group for the Study of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol 2011; 22: 1236-1242.
11. Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Niclella D, Aglietta M, Lonardi S, Corsi D, Turci D, Beretta GD, Fornarini G, Dapretto E, Floriani I, Zaniboni A; Italian Group for the Study of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous chemotherapy in advanced colorectal cancer: A randomised 'GISCAD' trial. Ann Oncol 2011; 22: 1236-1242.
12. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 2006; 24: 394-400.
13. Adams R, Wilson R, Seymour MT, Meade AM, Madi A, Cassidy J, Maughan TS. Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: A randomized non-inferiority trial (MRC COIN) [abstract 15LBA]. Eur J Cancer 2009; Suppl 7: 259.
14. Tveit K, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Kure E, Ikdahl T, Skovlund E, Christoffersen T. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group [abstract 365]. J Clin Oncol 2011; 29 Suppl 4: 10.
15. Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS. Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial [abstract 4010]. J Clin Oncol 2008; 26: 180.
16. Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012; 17: 15-25.